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Summary A study involving the measurement of glutathione S-transferase activities and isoenzyme distribu-
tions in human ovarian tumours has been carried out. These tumours have been obtained either at initial
debulking surgery, prior to cytotoxic chemotherapy, or at second look laparotomy following chemotherapy.
The response rates of these two groups to chemotherapy differ markedly, wtih patients who have relapsed
following initial chemotherapy showing a reduction in response rates to subsequent chemotherapy. Analysis of
these data show no statistically significant differences between the glutathione S-transferase activity or
isoenzyme distribution in these two groups ofpatients. Significant differences were observed in the glutathione-
S-transferase activities (GST) between tumours and normal ovaries. GST activities in pre-chemotherapy
tumours (n = 33, P = 0.01) and post-chemotherapy tumours (n = 20, P = 0. 001) where significantly higher
than the GST activity in normal ovaries (n = 15). One feature was the expression of the basic isoenzyme which
is expressed more in normal ovaries than in tumours. No differences in these parameters were observed in
normal peritoneal tissue taken from patients before or after chemotherapy. These data do not support the
hypothesis that changes in glutathione S-transferase enzyme activity or isoenzyme expression are major
determinants of response to chemotherapy in ovarian tumours.
The use of platinum drugs has increased the response rates
seen in patients with epithelial ovarian cancer (- 70%,
Gurney et al., 1990). Modem combined drug therapy includ-
ing a platinum containing agent can be expected to produce
response rates of 60-80% (Ozols & Young, 1984). Patients
relapsing following therapy have a much lower response rate
to the same or alternative chemotherapy with response rates
in the order of 20% (Nash & Young, 1988; Zwelling, 1988).
The mechanisms by which cells can become resistant to
chemotherapy have been the subject of much investigation.
The glutathione S-transferase enzymes, together with the ubi-
quitous tripeptide glutathione have been implicated in resis-
tance to a number of drugs including the platinum drugs
(Fujiwara et al., 1990). These enzymes have also been used as
markers for malignant and pre-malignant changes in a
number of tissues (Hall et al., 1990).
This work describes the glutathione S-transferase activity
and isoenzyme expression in ovarian tumours taken either
before chemotherapy (at initial debulking surgery) or follow-
ing combination chemotherapy (at second-look laparotomy).
Similar measurements were performed on normal peritoneal
and ovarian tissue collected at the time of oophorectomy for
benign gynaecological conditions.
Materials and methods
Patients
Ovarian tumour specimens were provided by gynaecological
surgeons throughout the North West of England. Samples
were frozen in liquid nitrogen within minutes of excision and
stored at - 80°C until processing. Tumour histology was
confirmed with the referring hospital and the presence of
malignant tissue in the biopsy samples confirmed by one of
the authors at the time of assay by routine histology.
Samples of normal ovary were collected from patients
undergoing routine prophylactic oophorectomy at the time of
pelvic surgery for benign gynaecological disease (Median
age = 46, range 39-54 years). Identical experimental proce-
dures were performed on both these and the tumour samples.
Wherever possible a sample of healthy peritoneal tissue was
taken to compare with tumour and normal ovary.
Chemotherapy
The patients receiving chemotherapy prior to second-look
laparotomy had received one of the following regimens:
Regimen A (n = 13) - carboplatin (300 mgm2) + cyclo-
phosphamide (600 mg m2) alternating with ifosfamide (5 g
m_2) and doxorubicin hydrochloride (50 mg m-2) at 4 week
intervals for six cycles.
Regimen B (n = 1) - single agent cisplatinum (100 mg m2)
once every 4 weeks for six cycles.
Regimen C (n = 4) - single agent carboplatin (400 mg m2)
once every 4 weeks for six cycles.
Regimen D (n = 2) - melphalan (10mg day') for 5 days,
for six cycles at 5 week intervals.
Regimen E (n = 1) - Ifosfamide (5 g m-2) and doxorubicin
hydrochloride (50 mg m-2) and 4 week intervals for six cycles.
Chemicals
All chemicals used in the laboratory studies were obtained
from the Sigma Chemical Company (Poole, Dorset, UK)
unless otherwise stated.
Preparation oftissue homogenates
Tissue was thawed, homogenised in buffer (0.1 M potassium
phosphate, pH 6.8, 4°C) using a mechanical blender (Poly-
tron 3000, 60 s, max power) followed by centrifugation (MSE
microfuge, 2 min, max. speed 12000g) to remove particulate
matter.
The protein concentrations of the supernatants were deter-
mined using the Biorad protein assay system according to the
manufacturer's instructions. All results were standardised to
unit protein concentration.
Measurement ofglutathione S-transferase activity
Enzyme activity was measured spectrophotometrically using
l-chloro-2,-4 dinitrobenzene (CDNB) and glutathione as
Correspondence: A.T. McGown.
Received 9 March 1992; and in revised form 29 May 1992.
17." Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 66, 937-942938 D. MURPHY et al.
cosubstrates (Habig et al., 1974). All enzyme activities were
standardised for protein content. Briefly cell homogenates
were incubated with CDNB.-(1 mM) in potassium phosphate
buffer (0.1 M, pH 6.5, 37°C) and the increase in absorbance
recorded at 350 nm on a Beckma'n DU8 spectrophotometer
with kinetic accessory.
Immunohistochemistry
The glutathione S-transferase isoenzyme distribution was
determined using three rabbit polyclonal antibodies raised
against the human acidic (x), basic (a), and neutral (gs) forms
ofthe enzymes (Randall et al., 1990). Staining was performed
on 4 y paraffin embedded sections previously prepared from
the frozen tissue, following thawing in formalin (4%). Sec-
tions were dewaxed, alcohol fixed, air dried, and rehydrated
in phosphate buffered saline (PBS). Endogenous peroxidase
was blocked (30% H202, 0.3 g sodium azide in 3.3 ml PBS,
for 10 min). Following incubation in swine serum (10%,
15 min), the primary antibodies were added (30 min, 25°C,
1:400 dilution in PBS), the sample washed twice in PBS and
the second antibody added (Swine anti-rabbit peroxidase,
Daks, 1/100 dilution, 30 min). The peroxidase reaction was
developed using diaminobenzidine (0.5 mgml-') and hyd-
rogen peroxide (0.03%), followed by washing ( x 2, PBS) and
counterstaining in Mayers haematoxylin.
Each sample was processed in duplicate substituting only
the primary antibody for a control rabbit IgG, in order to
eliminate the possibility of non-specific staining. Similarly at
each staining session a sample of tissue known to express
each isoenzyme was processed in an identical manner. This
was used as a positive control of quality (anti i-kidney
tubule, anti "-liver, and anti a-liver).
Scoring
Each tumour was examined by two independent workers.
The samples were scored according to the following criteria
(a) 20-100% of the cells positive, (b) 1-19% positive (c) a
few isolated cells positive or (d) no positive staining.
Statistical analysis
Analysis was carried out using SPSS-X statistical package
(SPSS, Chicago, USA) on a Microvax 3600 minicomputer.
Results
A summary of the patient details, glutathione S-transferase
activities and isoenzyme expression is shown in Tables Ta and
Tb. Analysis of these' data reveals a significant difference in
glutathione S-transferase isoenzyme expression between nor-
mal ovaries (n = 15), and tumours (n = 55) (Table II). This
change, (absent or reduced levels in tumour compared with
normal ovary in the basic form of the enzyme) is highly
significant (P<0.001, Fisher's Exact Test). However no
difference was seen between the tumour specimens taken
before chemotherapy (n = 33) and those taken after
chemotherapy (n = 21) (P = 0.755, Fisher's Exact Test). No
differences in GST activity or isoenzyme expression were seen
in peritoneal tissue from the same groups of patients
(n = 39). No differences were seen in expression of the neut-
ral or acidic isoenzymes between the tumours and the normal
ovarian tissue. Expression of the neutral isoenzyme is either
low or absent in tumour, normal ovary, or peritoneum.
Ovary (both normal and tumour) shows high expression of
the acidic form (Figure la and b), whereas little is seen in
peritoneal tissue. Staining of normal ovary for the basic
isoform is shown in Figure Ic.
The glutathione S-transferase (GST) activity in tumours,
normal ovaries, and peritoneal tissue are shown in Table III.
Analysis of these data (Kruskall-Wallis) showed significant
differences in GST activity (P = 0.006) when normal ovaries,
pre-chemotherapy tumour (1st look), and post-chemotherapy
tumour (2nd look) were compared. Further analysis of the
GST activity data (Mann-Whitney) showed that the
differences occur between normal ovary (n = 15) and pre-
chemotherapy tumour (n = 33, P = 0.011), and between
normal ovary and post-chemotherapy tumour (n = 20, P =
0.001), but not between pre- and post-chemotherapy tumours
(P = 0.630), tumour tissues having higher levels of GST
activity than normal ovary.
Further analysis of these data showed that GST activity
was not related to:
(a) clinical response (Mann-Whitney), (P = 0.653).
(b) tumour histology (Kruskal-Wallis, P = 0.560).
(c) tumour differentiation state (Kruskal-Wallis, P=
0.874).
(d) figo stage (Kruskal-Wallis, P = 0.287).
(e) patient age (regression analysis, GSH P = 0.226, GST
P=0.777.
Discussion
The platinum drugs are amongst the most effective agents in
the treatment of ovarian malignancy. Their clinical usefulness
is limited both by toxicity and the development of resistance.
Glutathione and the glutathione S-transferase enzymes have
been implicated as an important factor is resistance to a
number of anti-cancer drugs including the platinum drugs,
cyclophosphamide, ifosfamide and doxorubicin hydroch-
loride (Zwelling, 1988; Randall et al., 1990; Nakagawa et al.,
1990; McGown & Fox, 1986). However several other
mechanisms of resistance have been suggested from in vitro
work including altered metallothionein content, increased
DNA repair, and reduced drug transport (Fujiwara et al.,
1990).
This work describes the glutathione S-transferase activity
and isoenzyme distribution in a number of human ovarian
tumour biopsies and normal ovaries. The tumour biopsies
have been taken either before the commencement of
cytotoxic chemotherapy or following the regimens described.
A statistical analysis of these data showed no significant
difference in glutathione S-transferase activity, or isoenzyme
distribution between tumours which have or have not been
exposed to cytotoxic chemotherapy. These, however, show
markedly different responses to therapy. A significant
difference in glutathione S-transferase activity and expression
of the basic isoenzyme was found when tumours are com-
pared to normal ovary. Both pre- and post-chemotherapy
tumours have higher levels of GST activity than normal
ovaries. Tumour tissue also showed reduced or undetectable
expression of the basic GST isoenzyme. No significant
differences were found in GST activity or expression between
peritoneal tissue taken from patients with non-malignant
disease (n = 8), patients with ovarian tumours who have not
undergone chemotherapy (n = 15) and those who had (n = 8)
(GST activity Kruskal-Wallis analysis, P = 0.41); isoenzyme
distribution, see Table TI).
Tumours can be broadly categorised into those which
show initial response to chemotherapy (intrinsic resistance)
or those which, following an initial response, relapse and are
refractory to further chemotherapy (acquired resistance). The
biochemical processes which cause this decrease in response
are complex. Studies to elucidate the mechanisms by which
tumours can overcome the effects of cytotoxic agents have
largely been carried out using cloned cell populations. These
cell lines are generally selected by drug challenge, usually
with a single agent, often express high levels of stable resis-
tance. These studies have uncovered an impressive range of
mechanisms which potentially unstable tumour cells can
adopt to overcome cellular damage. It is likely that many
novel mechanisms still await discovery.
However the clinical relevance of these mechanisms have
yet to be fully elucidated. The development of resistance is a
complex process and involves alterations in a number of
cellular processes. It is difficult to know the precise contribu-GLUTATHIONE S-TRANSFERASE ACTIVITY IN OVARIAN TUMOURS 939
Table I Patient details
a First look samples
Isoenzymes
Patient GST activity Acidic Basic Neutral
MT 82.1 (2.6) 4
NC - 4
FB 3.6 (0.07) 4
DG 61.6 (0.8) 4
LB - 1
HB 56.6 (1.6) 4
SW 341.9 (10.0) 4
DR 419 (12.9) 4
FW 10.4 (0.2) 4
CH 82.4 (2.0) 4
HE 31.8 (0.7) 4
HB 4.3(0.1) 4
GF 24.1 (0.3) 4
SK 92.6 (1.8) 4
EB' 16.0 (0.3) 4
MP 16.0 (0.3) 4
KL 21.4 (0.7) 4
EB2 57.0 (2.0) 4
GH 23.6 (0.9) 4
EH 2.2 (0.1) 4
SC 12.6 (0.4) 4
GM 23.6 (0.7) 4
MT 111.70 (7.0) 4
SH 230.0 (12.4) 4
YM 102.0 (3.9) 4
JO 64.0 (2.1) 4
JW - 4
PS 23.0 (0.4) 2
GP 516.0 (15.9) 4
SD 88.0 (2.7) 4
PM 134.0 (4.2) 4
JD1 90.0 (2.8) 4
EF 208.0 (6.2) 4
JD2 158.0 (3.7) 4
MO 148.0 (4.7) 4
RB 156.0 (3.1) 4
2
2
2
2
1
3
2
2
2
I
1l
1l
2
l
Residual disease Response to Differentiation Figo
after laparotomy Treatment treatment Histology state stage Age
No disease
No disease
Bulk
MRD
MRD
Bulk
Bulk
MRD
Bulk
MRD
MRD
No disease
Bulk
Bulk
No disease
Bulk
Bulk
MRD
No disease
MRD
MRD
Bulk
MRD
MRD
MRD
MRD
MRD
MRD
MRD
MRD
No disease
Bulk
Bulk
MRD
MRD
MRD
- - M Well
- - M Well
- U Poor
CB/CY/I/A CR E Moderate
E Poor
- - M Poor
CB/CY/I/A PR S Poor
M PD E Poor
CB/CY/I/A PR S Moderate
- - M Well
U Poor
- - U Moderate
E Poor
- - U Poor
CY PD E Well
- - U Moderate
- - U Moderate
- - E Moderate
- - S Well
- - M Poor
- - M Poor
- - S Moderate
CB/CY/I/A PR E Poor
M Poor
M Moderate
M PD E Poor
- M Poor
- - E Poor
- E Moderate
-- M Moderate
- - M Well
M PD M Moderate
CB/CY/I/A PD E Poor
CB/CY/I/A CR S Moderate
- - S Moderate
CB/CY/I/A PR U Poor
b Second look samples post chemotherapy
Isoenzymes Residual disease
after Ist look Response to Differentiation Figo
Patient GST activity Acidic Basic Neutral Treatment laparotomy treatment Histology state stage Age
SH 17.0 (0.3) 4 1 1 IFOS/ADR Bulk PR U Poor 3 53
RM - 4 1 1 CB/CY/I/A MRD PR U Poor 4 46
MG 26.0 (1.0) 4 1 1 CB/CY/I/A MRD PD E Poor 3 53
SH 5.4 (0.1) 4 1 1 CB/CY/I/A MRD PR S MOD 4 42
EB 54.1 (1.6) 4 1 1 CB/CY/I/A MRD PD S MOD 3 61
IF 31.0(0.6) 4 1 1 CB MRD PD M MOD 3 46
LT 10.34 (0.2) 4 1 1 M Bulk PD U Poor 3 71
RW 427.0 (8.5) 4 1 1 CB/CY/I/A Bulk PR S Poor 3 55
SD 117.0 (8.2) 4 2 1 CB/CY/I/A MRD PR S MOD 3 65
MM 205.0 (8.2) 4 1 1 CIS MRD Static E MOD 3 64
SW 68.0 (2.0) 4 1 1 CB/CY/I/A Bulk PR S Poor 3 66
KW 97.0 (3.6) 4 1 1 CB/CY/I/A MRD PD E Poor 3 56
EC 56.0 (1.1) 4 1 1 CB Bulk PD S MOD 3 40
PH 91.0 (2.7) 4 1 1 CB/CY/I/A MRD PR E Poor 3 62
DG 137.0 (4.1) 4 2 1 CB MRD PD U Poor 3 66
MK 72.0 (1.8) 4 3 1 CB/CY/I/A Bulk PR S Poor 3 59
DR 78.0 (2.0) 4 1 1 M MRD PD S Poor 3 72
MM 107.00 (3.3) 4 1 1 CB/CY/I/A Bulk Static M MOD 2 60
DM 84.0 (3.8) 4 1 1 CB/CY/I/A MRD PD E Poor 3 42
GA 92.0 (3.1) 4 1 1 CB MRD PD S Poor 3 59
PS 122.0 (4.7) 4 1 1 CB/CY/I/A Bulk Static E Poor 3 48
GSH level - nmoles/mg/protein (mean s.d.). GST activity nmolesconjugate/min/mgprotein (mean s.d.). Isoenzyme Distribution
- % ofcells
staining positive.
- nocells,2
- few isolated cells, 3-20% cells, 4
- 20% ofcells. Treatment Drugsused: CB
-carboplatin, CY
- Cyclophosphamide, A
- adriamycin, I - ifosfamide, M - melphelan. Response to treatment: CR complete response, PR partial response (> 50% reduction in tumour
volume), Static
- no change or < 50% reduction. PD
- progressive disease. Residual diseaseatlaparotomy: MRD -minimal residual disease lessthan
2 cm in maximum diameter. Bulk greater than 2 cm in maximum diameter. Histology: U
- unclassifed, E
- endemetroid, M - mucinous, S - serous.
Differentiation state: poor, moderate, well. Stage-Figo classification.
1 48
1 62
3 72
3 70
3 77
3 62
3 60
3 72
3 52
2 71
3 80
1 65
3 83
3 62
1 73
3 80
3 76
2 70
1 58
3 65
3 62
3 64
1 66
3 66
3 60
3 67
3 60
1 74
3 51
3 31
1 30
3 68
3 64
3 28
3 74
3 53940 D. MURPHY et al.
a b
c
Figure 1 a Demonstrates the predominantly intracytoplasmic staining found in the majority of tumour cells when stained with
antibody to the acidic form of GST. This section was taken from a 28 year old patient with a stage III serous cystadenocarcinoma
at first look surgery prior to chemotherapy. b Demonstrates a section from the same patient stained for endogenous peroxidase
activity. c Demonstrates a normal ovary stained with the basic form of GST.GLUTATHIONE S-TRANSFERASE ACTIVITY IN OVARIAN TUMOURS 941
Table II GST isoenzyme distribution in tumojir, normal ovary and peritoneum
Proportion Number ofsamples
ofcells Ovary Peritoneum
expressing
GST 1st 2nd Fisher's 1St 2nd Fisher's
isoenzymes Normal Look Look Exact Normal Look Look Exact
Acidic isoenzymes
No cells 1 3 1
Few isolated = 1.000 8 16 7 P=0.280 <20%
> = 20% ~15 34 21 2
Basic isoenzymes
No cells 27 18 P<0.0O1 3 8 4
Few isolated 7 2 P<0.00l 6 11 6
Normal
vs 1st LookI
<20% 6 2 1 Normal P 0.819
vs 2nd Look
P=0.755
> = 20% ~9 Ilstvs2nd
Look
Neutral isoenzymes
Nocells 15 32 21 7 12 9
Fewisolated 4 P=0.177 2 7 2 P=0.586 <20%
>= 20%
Table III GST activity in ovarian tumour, normal ovary and peritoneum
No of
Tissue samples Mean Median Range St. Dev.
Normal ovary 15 30.00 27.00 10.0-66.00 21.50
1st look 33 121.95 82.10 2.21-652.90 153.33
2nd look 20 94.84 81.00 5.42-427.00 91.90
Peritoneum 10 11.88 8.00 1.90-30.00 10.29
Peritoneum 19 19.15 17.00 2.00-45.00 13.95
(at 1st look)
Peritoneum 8 20.06 12.09 .08-49.00 20.56
(at 2nd look)
tion of each of these individual changes to the overall
decrease in sensitivity seen in the tumour cells.
Tumours are heterogeneous and also may show a wide
range of enzyme activities. Any study which uses tumour
homogenates can only give an average value for the tumour.
Obviously this cannot give any information about the
existence of sub-populations of tumour cells with altered
drug sensitivities. Similarly the contribution from normal
cells, dying cells, and connective tissue within the tumour
cannot be accurately measured. Any interpretation of the
GST activity reported in this study must take these limita-
tions into account. The use of antibodies on tissue sections
followed by microscopical analysis allows expression of the
GST isoenzymes to be observed even in sub-populations of
cells within the tumour. However this is a qualitative
method, and it would be informative to quantify the expres-
sion of each isoenzyme by western blotting. This would be
particularly useful for a better characterisation of the appar-
ent decrease in expression of the basic isoform observed in
tumours.
This study compares two populations - tumours taken either
before or following extensive chemotherapy. The treatment
received by these ladies is, generally, a combination of
platimum drugs, doxorubicin hydrochloride, and an alkylating
agent. Hence the tumour may exhibit resistance to one or all
the drugs used. Therefore it is important to try to study as
wide a range of proven resistance mechanisms as possible.
Glutathione and the glutathione S-transferases have been imp-
licated in resistance to the platinum drugs, doxorubicin hydro-
chloride, and alkylating agents. These enzymes may therefore
be considered as a potential mechanism which may be involv-
ed against the drug cocktail used to treat ovarian tumours.
The work of Lewis et al. (1988) showed increased GST and
GSH in two ovarian cell lines derived from a patient during
a course of therapy. This paper also described differences
between cells in logarithmic growth compared to confluent
cultures. This difference may be important as a determinant
of response, as the ovarian tumours are composed mainly of
non-cycling cells. However the production of cell lines from
tumour biopsy material imposes selective pressures which
may result in the cloning of non-representative cell lines.
A study of this type has two major drawbacks. Firstly, it
would be better to obtain sequential biopsies from the same
patient before and after therapy. A study of this design is at
present underway. A comparison of populations &pre-
chemotherapy tumours, and normal ovaries) such as that
made in this study may not reveal small alterations in GST
activity which occurs in tumours following chemotherapy.
However no large changes were observed. Computer simula-
tions on the data showed that statistical significance would
have been attained if the post-chemotherapy tumours had
approximately double the GST activity of the pre-chemo-
therapy tumours. This increase is less than that reported for
many drug resistant cell lines (Misty et al., 1991). Similarly
no alterations in isoenzyme distribution between pre- and
post-chemotherapy tumours was seen.
Secondly, as already discussed the GST activities represent
average values for all cells within the tumour. Evidence for942 D. MURPHY et al.
tumour heterogeneity was seen in the distribution of isoen-
zyme expression with a tumour. However adjacent biopsies
from the same tumour or normal ovary showed no
significant differences in GST activity. Therefore we have
confidence that our measurement of GST in biopsies gives a
measure of the average value within the tumour.
In summary these data show that tumours show elevated
of glutathione S-transferase activity when compared with
normal ovaries. No significant difference was seen betwen
tumours excised before or after chemotherapy. These data do
not support the hypothesis that large changes in glutathione
S-transferase activity are a major determinant of resistance to
chemotherapy in ovarian tumours. The possibility still exists
that sub-populations of resistant cells exist within the
tumour. Similarly if chemotherapy induced only small
changes a study of this type may have difficulty in identifying
these in a tissue which shows a wide range of intrinsic GST
activities. These questions will be better answered by a study
using sequential biopsies obtained in the same patient before
and after chemotherapy.
This work was supported by the Cancer Research Campaign.
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